Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Nov 21, 2026
TickeronGET DAILY SIGNALS
Tilray Brands (TLRY): Can the Stock Reach the $6.20 Analyst Target?

Tilray Brands (TLRY): Can the Stock Reach the $6.20 Analyst Target?

Key Takeaways

  • The central target of $6.20 is the arithmetic mean of eight verified analyst price targets reviewed for this analysis, rounded from roughly $6.22.
  • With the stock near $1.89, reaching $6.20 would require a gain of about 228% — a very large move by any standard.
  • Individual targets span a wide range, from a low of $2.79 (Haywood) to a high of $13 (Jefferies), reflecting unusually deep disagreement.
  • The strongest supports are rapid beverage growth from the BrewDog acquisition, expanding European medical cannabis, and cost-cutting that lifted fiscal 2027 guidance.
  • The biggest risks are persistent net losses, negative free cash flow, a shrinking Canadian cannabis business, and uncertain U.S. cannabis reform.
  • For more context, explore Major News, Today's Price Move, the Forecast, and Earnings pages.

Analyst Price Targets and Consensus View

Eight current targets were reviewed from sources identifying the analyst, firm, target and date. The range is extremely wide — roughly $2.79 at the low end to $13 at the high end — and the arithmetic mean of the eight is about $6.22, which rounds to the central target of $6.20. Bullish names cluster at the top: Jefferies reiterated a Buy with a $13 target in late October 2026, and Roth MKM held a $10 Buy. Cautious voices sit near the bottom: Haywood cut to $2.79, while Canaccord Genuity and Alliance Global Partners each stand at $4 with Hold ratings. In between, ATB Cormark sits at $5 and TD Cowen at $4.50. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

Notably, most revisions have been downward this year — Alliance Global and Canaccord trimmed, Bernstein lowered its target from $10 to $6.50 — even as Roth Capital upgraded the stock to Buy earlier in 2026. The spread between $2.79 and $13 signals that analysts are not debating whether the business is challenged, but how much of the diversification story will ultimately translate into value.

Current Market Position and Path Toward the Target

The stock closed near $1.89 in mid-November 2026, within pennies of its $1.87 52-week low and about 88% below its $15.70 52-week high, with a market capitalization of roughly $279 million. To reach $6.20, the shares would need to appreciate about 228% — a very large move that would likely require a fundamental re-rating, not just a relief rally.

The path toward that level runs through demonstrated profitability. Tilray reported record fiscal 2026 revenue of $915 million (up 11%) and adjusted EBITDA of $61 million, and raised its fiscal 2027 adjusted EBITDA guidance to $70 million to $75 million. First-quarter fiscal 2027 revenue reached a record $257 million, driven by an 82% jump in beverage sales after the BrewDog acquisition, even as cannabis net revenue fell 13%. Investors will need to see these trends convert into sustained positive earnings before a multiple of the current share price becomes credible.

What Could Support a Move Toward the Target

The most concrete supports are operational. BrewDog, acquired for about $54 million, has returned to profitability and now anchors a beverage segment that is Tilray's largest revenue source. International medical cannabis is growing quickly — European, Middle East and Africa revenue rose roughly 71% in the latest quarter — with the company holding a strong position in Germany's medical market. Management is also consolidating Canadian facilities for roughly $30 million in annualized savings, reduced debt to a net cash position, and ended fiscal 2026 with about $235 million in cash and marketable securities. Renewed U.S. rescheduling headlines periodically spark sharp sector rallies, though Tilray itself has no reported U.S. cannabis revenue.

What Could Prevent the Target From Being Reached

The headwinds are substantial. Tilray remains unprofitable on a net basis, posted a roughly $40 million quarterly net loss, and generated negative free cash flow of about $27 million in its latest quarter. Canadian adult-use cannabis sales continue to decline under intense price competition, and adjusted EBITDA actually fell year over year in the first quarter. The company has also relied on at-the-market share offerings, which shareholders flagged as a dilution concern. Finally, U.S. federal cannabis reform remains delayed and would principally benefit U.S. operators rather than a Canadian producer, meaning the stock's historic catalyst may not materialize as hoped.

Technical Levels and Market Structure

Technically, the picture is weak. The stock trades in a clear downtrend, below its 20-day and 60-day moving averages, and sits essentially at its 52-week low of $1.87 — a critical support zone alongside the round $2.00 level. Overhead, prior breakdown areas near $2.50 to $3.00 act as resistance, followed by the higher $4.00 to $5.00 band where several analyst targets cluster. A sustained move above the low-$2 range would be an early sign of stabilization, while a loss of $1.87 would mark fresh multi-year lows.

Time Horizon and What Investors Should Monitor

Analyst price targets typically reflect a roughly 12-month horizon, and the eight targets here span several months of activity, with most dated from early October 2026 onward. Key items to watch include the next earnings report, progress on adjusted EBITDA toward the $70 million to $75 million fiscal 2027 guidance, free-cash-flow generation, Canadian cannabis stabilization, European medical growth, and any concrete movement on U.S. rescheduling. Dilution from share issuance and integration of the beverage portfolio also warrant close attention.

Leveraging Tickeron’s AI Daily Buy/Sell Signals

For traders who prefer a data-driven complement to fundamental research, I turned to Tickeron’s AI Daily Buy/Sell Signals. This tool uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell or Hold signals from shifting market conditions, technical behavior and AI-driven analysis. It helps surface opportunities, monitor existing positions and detect changing trends more efficiently. For a volatile name like TLRY, it offers a structured way to follow momentum and turning points alongside the analyst views.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: TLRY

Contributor

Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.


Momentum Indicator for TLRY turns negative, indicating new downward trend

TLRY saw its Momentum Indicator move below the 0 level on November 10, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 79 similar instances where the indicator turned negative. In 73 of the 79 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for TLRY turned negative on November 17, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In 39 of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where TLRY declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for TLRY entered a downward trend on November 20, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator shows that the ticker has stayed in the oversold zone for 5 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an Uptrend is expected.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +16.08% 3-day Advance, the price is estimated to grow further. Considering data from situations where TLRY advanced for three days, in 166 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.

TLRY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron PE Growth Rating for this company is 16 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Valuation Rating of 22 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.254) is normal, around the industry mean (6.379). P/E Ratio (-2.679) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (0.481) is also within normal values, averaging (183.387).

The Tickeron Price Growth Rating for this company is 91 (best 1 - 100 worst), indicating slightly worse than average price growth. TLRY’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TLRY’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.

Notable companies

The most notable companies in this group are Teva Pharmaceutical Industries Limited (NYSE:TEVA), ZOETIS (NYSE:ZTS), Elanco Animal Health (NYSE:ELAN), Bausch Health Companies (NYSE:BHC), BioCryst Pharmaceuticals (NASDAQ:BCRX), Tilray Brands Inc. (NASDAQ:TLRY), Aurora Cannabis (NASDAQ:ACB), Canopy Growth Corp (NASDAQ:CGC), Journey Medical Corp (NASDAQ:DERM).

Industry description

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

Market Cap

The average market capitalization across the Pharmaceuticals: Generic Industry is 4.46B. The market cap for tickers in the group ranges from 2.12K to 68.49B. MKGAF holds the highest valuation in this group at 68.49B. The lowest valued company is CANQF at 2.12K.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Generic Industry was -8%. For the same Industry, the average monthly price growth was -11%, and the average quarterly price growth was -13%. AKAN experienced the highest price growth at 211%, while PRFX experienced the biggest fall at -39%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Generic Industry was -4%. For the same stocks of the Industry, the average monthly volume growth was 37% and the average quarterly volume growth was 47%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 43
P/E Growth Rating: 56
Price Growth Rating: 62
SMR Rating: 87
Profit Risk Rating: 83
Seasonality Score: 5 (-100 ... +100)
AI Screener 3
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a holding company, whose subsidiaries engages in research, cultivation, processing and distribution of medical cannabis

Industry PharmaceuticalsGeneric

Industry
Biotechnology
Address
265 Talbot Street West
Phone
+1 844 845-7291
Employees
3595
Web
https://www.tilray.com
Interact to see
Advertisement
The ADR gapped lower in premarket trading and was at $335.71 in early regular-session trading, -4.65% from Thursday's close of $352.09. The move extends a global AI and chip unwind: investors are cutting crowded semiconductor bets on stretched valuations, rising sector debt, data-center opposition and Nvidia's leadership turmoil, and Nvidia's strong quarter failed to calm sentiment.
Micron shares slid from Thursday's $690.44 close to $635.41, a -7.97% loss, deepening during Friday's regular session after an already soft premarket. The decline was sector-driven, not company-specific: investors kept unwinding AI exposure as Anthropic fell back after its debut, while hawkish Fed comments and doubts about Nvidia's leadership and AI spending returns pressured chip valuations.
Meta Platforms fell from a $596.22 previous close to $583.40, a -2.15% move, with the decline built in premarket trading and held through early Friday action after Thursday's -3.27% drop. The drop was sector-driven, not company-specific: Anthropic slid roughly -6% to -10% premarket on its second trading day, reviving doubts that AI spending will generate returns, and AI-linked megacaps sold off broadly with Nasdaq 100 futures down about -1.5%.
ANT dropped from Thursday's record-debut close of $97.17 to about $88.56 in Friday premarket trading, a -8.86% move ahead of the opening bell, still above its $83 IPO price. The decline came from a broad AI and technology selloff rather than any Anthropic-specific disclosure: Nvidia and AMD traded lower premarket, index futures were sharply down, and renewed doubts over AI spending and valuations drove profit-taking after the +17.07% first-day gain.
IREN dropped -8.33% to $13.21 from Thursday's $14.41 close, with weakness building in premarket and extending through the first hour of regular trading. The decline extends a sector-wide neocloud rout: Anthropic's post-IPO slide and turmoil at Nvidia revived doubts about debt-funded AI data center spending, dragging CoreWeave and Nebius down with it; no IREN-specific news was released.
Tilray Brands (TLRY): Can the Stock Reach the $6.20 Analyst Target?